What is the maximum recommended dose of paroxetine (Paxil) for an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Dose of Paxil (Paroxetine)

The maximum recommended dose of paroxetine (Paxil) for adults is 50 mg/day for major depressive disorder, 60 mg/day for panic disorder and obsessive-compulsive disorder, and 75 mg/day for panic disorder with Paxil CR formulation 1.

Dosing by Indication

Major Depressive Disorder

  • Starting dose: 20 mg/day (immediate-release) or 25 mg/day (Paxil CR)
  • Maximum dose: 50 mg/day (immediate-release) or 62.5 mg/day (Paxil CR)
  • Increase in 10 mg increments (immediate-release) or 12.5 mg increments (CR) at weekly intervals 1
  • Most patients respond adequately to 20 mg/day; higher doses should only be used if no response after 1-3 weeks 2

Panic Disorder

  • Starting dose: 10 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
  • Maximum dose: 60 mg/day (immediate-release) or 75 mg/day (Paxil CR)
  • Increase in 10 mg increments at weekly intervals 1

Obsessive-Compulsive Disorder

  • Effective doses: 40-60 mg/day
  • Maximum dose: 60 mg/day
  • The 20 mg/day dose is NOT effective for OCD; doses of 40 mg/day and 60 mg/day show significant efficacy 3

Social Anxiety Disorder

  • Starting dose: 20 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
  • Maximum dose: 50 mg/day (immediate-release) or 37.5 mg/day (Paxil CR)
  • Effective range is typically 20-50 mg/day 4

Generalized Anxiety Disorder

  • Maximum dose: 50 mg/day

Premenstrual Dysphoric Disorder

  • Maximum dose: 25 mg/day (Paxil CR only)

Special Populations

Elderly Patients (≥65 years)

  • Starting dose: 10 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
  • Maximum dose: 40 mg/day (immediate-release) or 50 mg/day (Paxil CR)
  • Elderly patients have significantly higher plasma concentrations and prolonged half-life, requiring dose reduction 5, 1

Patients with Hepatic or Severe Renal Impairment

  • Starting dose: 10 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
  • Maximum dose: 40 mg/day (immediate-release) or 50 mg/day (Paxil CR)
  • These patients have increased bioavailability and reduced clearance 1

Critical Safety Considerations

CYP2D6 Poor Metabolizers

Paroxetine is metabolized primarily by CYP2D6, which exhibits genetic polymorphism. CYP2D6 poor metabolizers have 3.8-fold higher paroxetine concentrations than extensive metabolizers and may require only 25% of the standard starting dose 6. CYP2D6 intermediate metabolizers have 2.2-fold higher concentrations and may require 50% of the standard dose 6.

Drug Interactions

Paroxetine has the highest inhibitory constant for CYP2D6 of all antidepressants (Ki = 0.065-4.65 micromoles), making it prone to significant drug-drug interactions 7. It also inhibits CYP3A4 8. Avoid combining with MAOIs, other serotonergic drugs, and drugs metabolized by CYP2D6 8.

Discontinuation Syndrome

Paroxetine has the highest risk of discontinuation syndrome among SSRIs due to its short half-life and potent serotonin transporter affinity 8. Always taper slowly over 10-14 days when discontinuing 5.

Pregnancy and Breastfeeding

Paroxetine is not preferred for new episodes during pregnancy due to associations with birth defects and gestational hypertension 9. However, switching medications during ongoing treatment is discouraged 9. If used, neonates require observation for withdrawal symptoms 1.

Suicidality Risk

Paroxetine carries a black box warning for treatment-emergent suicidality, particularly in adolescents and young adults aged 18-24 years, with the highest risk in the first month of treatment 10, 11. Close monitoring is essential, especially during dose changes 12.

Common Pitfalls

  • Do not use 20 mg/day for OCD—this dose is ineffective; start at 40 mg/day 3
  • Do not exceed 40 mg/day in elderly patients or those with hepatic/renal impairment 1
  • Do not combine with tamoxifen—paroxetine inhibits conversion to active endoxifen, increasing breast cancer mortality risk 11, 7
  • Do not abruptly discontinue—paroxetine has the highest discontinuation syndrome risk among SSRIs 8

References

Research

Optimal dose regimen for paroxetine.

The Journal of clinical psychiatry, 1992

Research

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.

Therapeutic drug monitoring, 2023

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Guidelines on treatment of perinatal depression with antidepressants: An international review.

The Australian and New Zealand journal of psychiatry, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.